<DOC>
	<DOCNO>NCT00334958</DOCNO>
	<brief_summary>The primary objective study evaluate effect rufinamide total partial seizure frequency adolescent adult patient refractory partial onset seizure currently inadequately treat maximum three stable antiepileptic medication . Secondary objective evaluate effect rufinamide secondary exploratory outcome , confirm safety profile rufinamide , ass relationship rufinamide plasma concentration efficacy .</brief_summary>
	<brief_title>Rufinamide Given Adjunctive Therapy Patients With Refractory Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Male female patient 12 80 year age , inclusive . 2 . Diagnosis epilepsy partialonset seizure without secondarily generalize seizures accord International League Against Epilepsy Classification Epileptic Seizures ( 1981 ) . Diagnosis establish clinical history , electroencephalogram ( EEG ) compute tomography/magnetic resonance imaging ( CT/MRI ) brain perform within last 10 year consistent localizationrelated epilepsy . 3 . Noncontrolled partial seizure despite treat least two different antiepileptic drug ( give concurrently sequentially ) least two year . 4 . Patient willing participate write consent sign patient legal guardian prior enter study undergo study procedure . If write consent provide legal guardian patient unable , assent patient must also obtain . 5 . Reliability willingness patient make available study period , ability record seizures report adverse event caregiver record seizures report adverse event . 6 . Female patient nonchildbearing potential reason surgery , radiation , menopause ( least one year post onset ) ; childbearing potential use two approve method contraception ( intrauterine device [ IUD ] , implant , oral contraceptive , barrier method plus spermicide ) . Use lowdose estrogen oral contraceptive ( `` minipill '' ) alone permit . Female patient childbearing potential must confirm negative serum pregnancy test screen negative urine pregnancy test prior randomization , agree continue use two approve method contraception followup visit ( Visit 8 ) 30 day final dose study medication , whichever longer . 7 . At least six seizure prospective Baseline Phase ( 56 day ) 21day seizurefree period . Simple partial seizure without motor sign include determine criterion . 8 . Current treatment maximum three approve antiepileptic drug , evidence noncompliance ongoing AED therapy . 9 . Stable dose ( ) AED ( ) one month prior screen . 10 . If use vagal nerve stimulator , must implant least six month prior randomization . Stimulator parameter may change least one month prior screen thereafter study . Magnet use allow , must document throughout study . A vagal nerve stimulator count AED purpose inclusion trial . EXCLUSION CRITERIA : 1 . Participation study involve administration investigational compound within one month Visit 1 ( Screening ) , within five halflives previous investigational compound , whichever longer ; prior exposure rufinamide . 2 . Presence nonmotor simple partial seizure . 3 . Presence generalize epilepsy seizure , absence , myoclonic epilepsy , LennoxGastaut syndrome . 4 . History status epilepticus past year seizure cluster individual seizure count . 5 . Evidence clinically significant disease ( cardiac , respiratory , gastrointestinal , hepatic , hematologic renal disease , etc . ) opinion Investigator could affect patient 's safety trial conduct . 6 . Clinically significant ECG abnormality . 7 . Patients diagnosis major active psychiatric disease exclude study . However , patient take stable dose either selective serotonin reuptake inhibitor ( SSRI ) antidepressant drug serotonin norepinephrine reuptake inhibitor ( SNRI ) antidepressant drug diagnose depressive disorder include long SSRI SNRI period two month long randomization . Other antidepressant medication allow . 8 . Progressive central nervous system ( CNS ) disease , include degenerative CNS disease progressive tumor . 9 . Occurrence psychogenic seizure previous year . 10 . History drug abuse and/or positive finding urinary drug screening , prescribe medication 11 . History alcohol abuse past two year . 12 . History suicide attempt within previous 10 year . 13 . Multiple drug allergy ( dermatological , hematological organ toxicity ) one severe drug reaction ( ) . 14 . Concomitant use felbamate use felbamate within two month prior Visit 1 . 15 . Frequent need rescue benzodiazepine ( month ) . 16 . Patients know hypersensitivity rufinamide , triazole derivative , excipients use formulation . 17 . Concomitant use vigabatrin . Patients take vigabatrin past must vigabatrin least five month prior Visit 1 must evidence clinically significant abnormality visual perimetry test . 18 . All Patients diagnosis Congenital Short QT Syndrome . Patients family history Congenital Short QT Syndrome may exclude basis Investigator 's clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>